1. Introduction {#s0005}
===============

Efforts to improve the predictive capacity of existing cardiovascular risk-scoring models have been intense and have included the study of both novel blood and imaging biomarkers ([@bb0065]). Despite this, better and affordable tools to predict cardiovascular risk are still needed to avoid misclassification of "high risk" patients and resultant over- or under-treatment ([@bb0185]).

Atherosclerosis, the main pathological entity that leads to cardiovascular events, is a chronic inflammatory disease in which the innate and adaptive immune systems can play pathological or protective roles, depending on context ([@bb0060]). Although total serum immunoglobulins (Igs) are not normally considered as relevant to clinical CV disease, there is abundant evidence in the preclinical literature to suggest links with atherosclerosis. Our group established that mice deficient in IgM develop marked acceleration of atherosclerosis ([@bb0095]). Moreover, passive immunization of mice with polyclonal IgM or IgG, or adoptive transfer of IgM-secreting B-1 cells, retards atherosclerosis progression ([@bb0105], [@bb0190], [@bb0085], [@bb0015], [@bb0135]). On the other hand, depletion of IgG-secreting B cells reduces atherosclerosis and their adoptive transfer accelerates it ([@bb0005], [@bb0080]). Whilst the weight of evidence favors IgM being protective, there is still uncertainty as to how IgG antibodies influence atherosclerosis, in view of the pathogenic potential of IgG Fc-mediated pro-inflammatory effector functions.

A previous study found that serum IgG but not IgM was associated with a higher risk of myocardial infarction in dyslipidemic patients ([@bb0075]), whilst another failed to show any association between IgG or IgM and risk of myocardial infarction in a general population ([@bb0100]). However, the roles of specific antibodies as biomarkers in atherosclerosis have been more extensively studied. These include antibodies directed against epitopes induced by oxidative modifications of low-density lipoprotein (LDL), in particular antibodies reacting with phosphorylcholine or adducted malondialdehyde (MDA), as well as many less well-defined epitopes ([@bb0090], [@bb0165]). In the Bruneck study, IgG antibodies against copper-oxidized LDL (heavily-oxidized LDL that includes MDA-LDL epitopes) were associated with higher risk of CV events, whilst IgM antibodies were associated with lower risk ([@bb0130], [@bb0175]). In contrast, the EPIC Norfolk study implicated IgG and IgM anti-MDA-LDL antibodies as possible modifiers of the risk associated with oxidative biomarkers, rather than independent predictors of coronary artery disease events ([@bb0125]). Recently, a study from Sweden has reported that individuals with low levels of antibodies against MDA-adducted LDL peptides are associated with significantly higher coronary acute event rate ([@bb0010]).

The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) was an independent, investigator-led, multicenter, randomized trial designed to compare two anti-hypertensive treatment strategies for the prevention of CV events in more than 19,000 hypertensive patients without a clinical history of CHD. Using a nested case-control substudy of ASCOT, we set out to test the hypothesis that total serum IgM and IgG levels, as well as antibodies to MDA-LDL, are negative risk factors for cardiovascular events in a hypertensive population. Our analyses incorporated adjustments for levels of C-reactive protein (CRP) and N-terminal pro-B-type natriuretic peptide (NtProBNP), which have previously been studied in the ASCOT population ([@bb0155], [@bb0180]).

2. Material and Methods {#s0010}
=======================

2.1. Study Design and Subjects {#s0015}
------------------------------

ASCOT was an independent, investigator-led, multicenter, randomized trial designed to compare two anti-hypertensive treatment strategies for the prevention of CV events in more than 19,000 hypertensive patients without a clinical history of CHD (9098 were randomized in the UK or Ireland). Hypertensive patients with three or more other risk factors for CV disease were eligible for inclusion in ASCOT. The detailed ASCOT protocol has been published previously and further information is available at <http://www.ascotstudy.org> ([@bb0140]). Informed consent was obtained from each patient and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the participating institutions research ethics committees. In the main cohort, the ASCOT-Blood Pressure-Lowering Arm (BPLA), subjects received a beta-blocker with a thiazide diuretic as required or a dihydropyridine calcium channel blocker (CCB) with an angiotensin-converting enzyme inhibitor as required ([@bb0150]). In addition to randomization into ASCOT-BPLA, those with a fasting total cholesterol of ≤ 6.5 mmol/L (250 mg/dL) were further randomized, using a factorial design, to either 10 mg atorvastatin daily or matching placebo (ASCOT-LLA) ([@bb0145], [@bb0045]). Baseline characteristics of participants and primary outcomes of each arm of the trial have been reported previously ([@bb0140], [@bb0045]).

For the purposes of this case-control study (CCS), all events of fatal coronary heart disease (CHD), symptomatic non-fatal myocardial infarction (MI), coronary revascularization, and fatal and non-fatal stroke occurring in the UK and Ireland during the ASCOT-BPLA study period between February 1998 and October 2005 were identified as cases. Subjects with established cardiovascular disease (CVD) at baseline (including peripheral vascular disease and previous history of stroke, transient ischemic attack and recorded other relevant CVD) were excluded from this CCS. Hence, the present report is based on a nested CCS drawn from ASCOT participants in the UK and Ireland, 485 of whom developed CV events (355 CHD and 130 strokes) during a median follow-up period of 5.5 years. Further details of the selection process into the study are shown in [Fig. 1](#f0005){ref-type="fig"}.

Subjects who were alive and free from CV events during the study period were selected from the same study population as controls. Up to three controls were matched to each case by age (± 1 year), sex and study entry time (± 90 days), with one control being used with two different cases to facilitate matching. The study population was restricted to those self-defined as of white European ethnicity.

2.2. Endpoint Adjudication {#s0020}
--------------------------

All cases suspected of fulfilling criteria for the fatal and non-fatal events were classified by the Endpoint Committee. This included endpoints notified by investigators and potential silent MIs identified by the core ECG laboratory. All the documentation for each potential endpoint was reviewed independently by two of the Endpoint Committee members. In the event of disagreement, a third member the Endpoint Committee adjudicated. Final classification required agreement between two members of the Endpoint Committee. The Endpoint Committee met to resolve such disagreements and "grey cases."

2.3. Measurements {#s0025}
-----------------

All major cardiovascular disease (CVD) risk factors incorporated in the FRS were determined at baseline ([@bb0140]). Sera were prepared and aliquoted at entry to the study, and stored at − 70 °C prior to analysis. Serum IgM and IgG, and anti-MDA-LDL antibodies, were measured by enzyme-linked immunosorbent assay (ELISA) (see below). Other laboratory tests (including CRP and NtProBNP) were performed as previously described ([www.ascotstudy.org](http://www.ascotstudy.org){#ir0010}) ([@bb0155], [@bb0180]).

2.4. Immunoglobulin and Anti-MDA-LDL Antibody Level Measurements by ELISA {#s0030}
-------------------------------------------------------------------------

All ELISAs were conducted blindly with both cases and controls mixed according to random laboratory sample number. Personnel conducting assays were blind to patient-specific data and not aware of the statistical analysis plan. The intra-plate variability for all assays was below 3% and inter-plate variability below 13%, with assay ranges that span well above and below expected normal ranges for total IgG and IgM and well below and above the study range for IgG and IgM anti-MDA-LDL (Supplementary Methods Table 1).

Total IgG and IgM antibody levels were measured using capture ELISA. Briefly, either goat anti-human IgG or mouse anti-human IgM (Southern Biotech, Birmingham AL) was used to capture either IgG or IgM respectively. Detection antibodies used were either biotinylated goat F(ab\')² anti-human IgG or biotinylated mouse anti-human IgM (both Southern Biotech). Detection was with HRP-conjugated streptavidin (R&D Systems, Minneapolis, MN) followed by 3,3′,5,5′-tetramethylbenzidine (TMB) (Sigma Aldrich, UK), and the reaction was stopped with 0.5 M H~2~SO~4.~ Optical densities were measured with a Synergy HT microplate reader (BioTek, USA) at wavelength 450 nm. Once background was subtracted, results were expressed in Units (U). Cut off and tertile as well as interquartile values in mg/mL for total IgG and IgM were interpolated via standard curve fit using standard ELISA methodology in PRISM 6 (GraphPad, La Jolla, Ca).

IgG and IgM anti-MDA-LDL antibody levels were estimated by ELISA against solid phase MDA-LDL. Briefly, MDA-LDL was prepared as described ([@bb0115]). The extent of modification was determined by the relative electrophoretic mobility of the LDL using pre-cast 0.6% agarose, 1.0% barbital buffer gels (Beckman Coulter, Fullerton, Ca) and with a carbonyl assay ([@bb0030]). IgG and IgM antibody binding to solid phase antigens was identified by mouse anti-human IgG (Cambridge Bioscience, Cambridge, UK) or biotinylated mouse anti-human IgM (Cambridge Bioscience) followed by horse radish peroxidase (HRP) conjugated rabbit anti-mouse Ig (Dako, Cambridgeshire, UK) or as above with HRP-conjugated streptavidin. The plates were read as above at an optical density of 450 nm (OD450), after which the background was subtracted. All serum anti-MDA-LDL sample values were corrected to a reference serum with a standard curve used on all plates and results expressed in Units (U).

All assays were optimized for serum concentration, secondary antibody concentration and timing of TMB reactions using representative sera. Standard curves were established for each of the assays on several representative sera and selected serum dilution was at the steepest part of the curve to achieve the highest sensitivity. Furthermore, standard curves were included for a control serum on each ELISA plate for quality control. The lower and higher limit of assay sensitivity for all assays are shown in Supplementary Methods Table 1. The intra-plate and inter-plate coefficients of variation (CoV) for all assays are in Supplementary Methods Table 2.

2.5. Statistical Methods {#s0035}
------------------------

Continuous variables are presented as means ± standard deviation (SD), and non-normally distributed variables as medians with interquartile range (IQR). Crude comparisons between cases and controls with regard to baseline characteristics were explored by *t*-tests, Mann-Whitney U or χ^2^ tests. Age- and sex-adjusted correlations between continuous variables were assessed using the Spearman rank-correlation coefficient (rho). The association between each of the antibodies and the risk of CV events was reported as an odds ratio (OR) obtained from a conditional logistic regression model: first by treating each log-transformed baseline antibody as a continuous variable giving an odds with 95% confidence intervals (CI) of having an event per 1 SD change; and, secondly, by categorizing variables into tertiles with the low tertile as reference. To assess the predictive role of Igs and specific antibodies beyond conventional risk factors, we established five statistical models. Model 1 was matched for age and sex but was otherwise unadjusted; model 2 was adjusted for traditional CV risk factors based on an extended Framingham risk model (smoking, baseline systolic blood pressure (SBP), high-density lipoprotein (HDL), total cholesterol (TC), body mass index (BMI), creatinine), as well as randomized anti-hypertensive and statin treatment; model 3 included paired antibody levels and serum Ig (i.e. IgM anti-MDA-LDL with IgM and IgG anti-MDA-LDL with IgG) to assess the effect of adjustment for total serum Ig; model 4 adjusted for log CRP and log NtProBNP in addition to the covariates in model 2. Collinearity was tested using the variance inflation factor (VIF), and model goodness-of-fit and calibration was assessed using a likelihood ratio test and the Hosmer Lemeshow statistic. To examine the extent to which baseline log-transformed variable improved discrimination and reclassified participants over risk thresholds, model 2 plus further adjustment for age and sex was used in an unconditional logistic model. This reference model was compared with models including each log-transformed variable using area under receiver operator curves (AUROC), net reclassification index (NRI) and integrated discrimination index (IDI) ([@bb0120]).

All statistics were conducted independently by a statistician that is blinded to the laboratory techniques, using SAS version 9.3 (SAS Institute Inc., Cary, NC) and Stata release 12 (Stata Corp, College Station, TX). A two-tailed p value \< 0.05 was considered to indicate statistical significance.

Discrimination of the different risk models was assessed by the areas under the receiver operating characteristic curves (AUROC) using the nonparametric approach of DeLong et al. ([@bb0050]). Likelihood ratio tests were performed to evaluate whether the global model fit improved after the addition of each of the antibody in turn. Model calibration was assessed with the Hosmer--Lemeshow goodness-of-fit test. We also computed the NRI as a continuous and category-based NRI and an integrated discrimination improvement (IDI) analysis. IDI is defined as the difference in the mean predicted probability of being a case and being a control in the model with the addition of antibody minus the difference in the mean predicted probability of being a case and being a control in the model without the antibody level included. We also investigated whether the use of combinations of total serum Igs and anti-MDA-LDL antibodies would improve risk prediction. In these analyses, each of these study antibodies was treated as a continuous variable. Further NRI analyses for the most significant independent markers was undertaken to test reclassification within FRS with categories (\< 10%, 10--20% and \> 20% risk) were selected to define as low, intermediate and high risk of CVD.

3. Results {#s0040}
==========

3.1. Baseline Characteristics {#s0045}
-----------------------------

1753 subjects (mean age 65.3 ± 7.62 years; 1486, 84.8% male) were included in this nested case-control analysis ([Fig. 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}) and had a median follow-up of 5.5 years (interquartile range, 5.0--6.0). Of the 470 cases that were analyzed ([Fig. 1](#f0005){ref-type="fig"}), there were 343 with CHD and 127 who had a stroke (see breakdown in [Table 1](#t0005){ref-type="table"} footnote). Those with a CV event had a worse cardiovascular profile, including traditional risk factors (SBP, diastolic blood pressure \[DBP\] and LDL), as well as higher CRP and NtProBNP as previously shown ([Table 1](#t0005){ref-type="table"}) ([@bb0155], [@bb0180]). Significantly higher total serum IgG and IgM levels were found in controls compared to cases ([Table 2](#t0010){ref-type="table"}). Levels of anti-MDA-LDL antibodies were also higher in controls, although this was not as pronounced as with total serum Igs, and indeed was only significant at p \< 0.05 for IgG anti-MDA-LDL antibodies ([Table 2](#t0010){ref-type="table"}).

3.2. Correlations and Interactions Between Variables {#s0050}
----------------------------------------------------

IgM anti-MDA-LDL antibody levels correlated strongly with total serum IgM (rho = 0.78, p \< 0.0001), and there was a weaker but still highly significant correlation for IgG anti-MDA-LDL with total serum IgG (rho = 0.36, p \< 0.0001) ([Table 3](#t0015){ref-type="table"}). Though statistically significant, correlations between serum IgM and IgG and between IgM anti-MDA-LDL and IgG anti-MDA-LDL were modest ([Table 3](#t0015){ref-type="table"}). Total IgG and IgG anti-MDA-LDL antibodies correlated weakly with CRP (rho = 0.13 and rho = 0.09 respectively). There was also a weak inverse correlation of IgG anti-MDA-LDL antibodies with LDL cholesterol (rho = − 0.085, p \< 0.001).

Serum Ig and anti-MDA-LDL antibodies among the controls did not strongly correlate with age, SBP, DBP or mean arterial pressure (MAP) (Supplementary Table S1). Interestingly, there was a clear correlation with sex, with total serum IgM and IgG, as well as IgM anti-MDA-LDL antibodies, being higher in women than in men (p \< 0.05 for each) (Supplementary Table S2).

3.3. Total Serum IgG and IgM Are Inversely Associated With CV Events {#s0055}
--------------------------------------------------------------------

Unadjusted, all Ig and specific antibody levels measured were inversely associated with risk of CV events ([Table 4](#t0020){ref-type="table"}, model 1). In the highest third compared with the lowest, total serum IgG levels had the strongest association with CV events (OR = 0.62 \[95% confidence interval, CI 0.47, 0.81\]; p = 0.0004), and the weakest association was seen with IgM anti-MDA-LDL (OR 0.76 \[0.58, 0.98\]; p = 0.037). Trends were similar when the data were evaluated as continuous variables per 1 SD. Associations between IgM anti-MDA-LDL antibodies and CV events were modestly attenuated by adjustment for the basic risk variables and were no longer statistically significant, but associations with total serum IgG and IgM, or with IgG anti-MDA-LDL, were little affected and retained significance ([Table 4](#t0020){ref-type="table"}, model 2). Thus, for total serum IgG, there was an OR of 0.62 (0.46, 0.82) comparing highest and lowest total IgG levels (p = 0.0007) or an OR of 0.81 (0.72, 0.91) per 1 SD increase in total IgG levels (p = 0.0003). Associations between IgG and IgM anti-MDA-LDL antibody levels and CV events were abolished after adjustment for total serum IgG and IgM levels respectively ([Table 4](#t0020){ref-type="table"}, model 3). The significant inverse associations of total serum Ig levels with events remained even after adjustment for the basic risk variables plus log-transformed CRP and NtProBNP ([Table 4](#t0020){ref-type="table"}, model 4). Total serum IgG remained the strongest predictor of protection after full adjustment in model 4 (OR 0.81 \[0.72, 0.91\] per one increase in SD, p = 0.003; OR 0.61 \[0.46, 0.82\] comparing upper and lower thirds, p = 0.0008).

When exploring the ability of Igs and specific antibodies to predict events linked to either CHD or stroke, it became clear that the relationships described above for total serum Ig levels are only significant for CHD ([Table 5](#t0025){ref-type="table"}) and not stroke (Supplementary Table S3). The unadjusted OR for the highest tertiles in predicting CHD was 0.42 for total IgG (p \< 0.0001) and 0.57 for total IgM (p = 0.001) ([Table 5](#t0025){ref-type="table"}). Further adjustments in models 2, 3 and 4 demonstrated that again anti-MDA-LDL antibodies were dependent on total IgG and IgM, and that total serum Ig levels are independent of basic risk variables, CRP and NtProBNP as predictors. A further analysis of all CV events excluding hemorrhagic stroke did not appreciably alter the results shown in [Table 4](#t0020){ref-type="table"} (Supplementary Table S4).

3.4. Total Serum IgG Significantly Improves Prediction of CV Risk {#s0060}
-----------------------------------------------------------------

Addition of each of total serum IgG, total serum IgM and IgG anti-MDA-LDL antibodies significantly improved model fit ([Table 6](#t0030){ref-type="table"}). The AUROC was significantly improved by total serum IgG (0.6391 vs. 0.6213, p = 0.009), whereas IgG anti-MDA, IgM anti-MDA or total serum IgM did not significantly increase AUROC. Addition of all four measures to the basic model improved model fit and AUROC (0.6421 vs. 0.6213, p = 0.011), but there was no difference in AUROCs between the basic model including just total serum IgG and the basic model containing all four measures ([Table 6](#t0030){ref-type="table"}).

The addition of total serum IgG to the basic model resulted in an absolute IDI of 0.9 (p \< 0.0001), and the highest NRI (17.6% and 7.5% for continuous and category-based NRI, respectively) ([Table 6](#t0030){ref-type="table"}). Total serum IgG also led to the greatest absolute number of subjects with CV events correctly reclassified: 52 (11.1%) to a higher risk category and 25 (5.3%) to a lower risk category ([Fig. 2](#f0010){ref-type="fig"}). Of the 1284 controls, 71 (5.5%) were correctly reclassified using total serum IgG to a higher risk category and 94 (7.3%) to a lower risk category ([Fig. 2](#f0010){ref-type="fig"}). [Fig. 3](#f0015){ref-type="fig"} demonstrates the clinically relevant reclassification into and out of the \< 10% risk category for CVD, with a clear advantage of adding in total serum IgG to the model. Total serum IgG also performed best for CV event risk reclassification (18.6 and 8.3%, for continuous and category-based NRI, respectively) in the extended basic model (basic model + CRP and NtProBNP) (Supplementary Table S5).

There was a much more pronounced improvement in model performance when studying CHD alone. The most significant increase in AUROC, and highest NRI and IDI were after the addition of total IgG to either the basic model or the extended model (Supplementary Tables S6 and S7). The finding that total serum IgG results in a continuous NRI of a 29.6% (p \< 0.0001) despite adjustment for the basic model, log CRP and log NtProBNP puts this measurement in the forefront of risk prediction of CHD in this hypertensive population (Supplementary Table S7). Basic models with addition of the other immunoglobulins did not perform better than the basic model plus only total IgG (Supplementary Table S6).

4. Discussion {#s0065}
=============

The main novel finding in this paper is that in patients with hypertension the total IgG serum level, and to a lesser extent the total serum IgM level, is an independent predictor of freedom from CV events in general and from CHD in particular. Furthermore, total serum Ig levels significantly improved risk classification for CV events. High IgG and IgM levels were not associated with freedom from stroke, probably reflecting its more heterogeneous underlying pathology.

Although IgG and IgM anti-MDA-LDL antibodies were also significantly associated with freedom from CV events, these correlated significantly with their respective total serum Ig levels. Indeed, total serum IgM and IgG were much stronger indicators of freedom from events, and the univariate significance of anti-MDA-LDL antibodies was lost after adjusting for total serum levels of the respective Ig class. It is clear however that our comparison of specific antibodies with total IgG and IgM levels was restricted to those against just one form of oxidized LDL (i.e. MDA-LDL) and it remains possible that other specific autoantibodies against modified LDL or other antigens could have greater negative or positive predictive ability. Nevertheless, our results indicate that adjustment for total Ig levels will need to form part of further analyses investigating specific antibodies as prognostic markers of CVD.

We postulate that the greater predictive power of total Ig levels reflects a broad role of the polyreactive antibody repertoire in cardiovascular protection. On the one hand, the composite antibody repertoire can be expected to contribute to the safe disposal of a variety of other endogenous atherogenic autoantigens besides modified LDL, including apoptotic cells and microparticles ([@bb0025], [@bb0040], [@bb0170]). On the other hand, the conventional role of antibodies in preventing bacterial infection may also be important for reducing the rate of atherosclerosis progression and reducing infection-triggered acute cardiac events ([@bb0160]). In this light, the greater predictive capacity of the total IgG level compared to IgM argues for the importance of a robust adaptive immune response. Certainly the relative roles of genetic and environmental influences in setting Ig levels merits further study ([@bb0035], [@bb0110]), and in this light it is interesting that serum IgG and IgM levels in our study were significantly higher in women, consistent with previous observations ([@bb0055]).

The strong negative association between IgG and IgM levels and CHD events needs to be considered in the context of other biomarkers that have been evaluated as adjuncts to traditional risk assessments. Although the ASCOT-CRP substudy concluded that measuring CRP had little utility in refining CV risk assessment beyond classical risk factors in the study population ([@bb0155]), a meta-analysis concluded that adding CRP to the risk assessment led to predicting one additional event over a period of 10 years for every 400--500 people screened ([@bb0070]). Not only did IgG levels remain highly significant in predicting protection from events after adjustment for CRP, they were also independent from NtProBNP which was previously shown to be a predictor of events in ASCOT ([@bb0180]).

A particularly important outcome of the study was the reclassification of more cases and less controls into the clinically relevant \> 10% risk categories and more controls with less cases in the \< 10% risk category by incorporating total serum IgG in the analysis. If confirmed in further cohorts, this has the potential to be used for more robust risk stratification in hypertension, thus redirecting primary prevention therapies towards those who would benefit the most.

Our findings are at odds with those of Kovanen et al. who showed that serum IgG levels (as well as IgA and IgE), but not IgM, were predictive of MI ([@bb0075]). However the two studies differ in entrance requirements, with that of Kovanen et al. being selected for dyslipidemia whilst ours was based on hypertension. It is possible that IgG levels in our study population might have been affected by hypertension, although we did not detect any correlations with SBP, DBP or MAP ([@bb0020]). It therefore remains to be seen to what degree our findings on the ASCOT population generalize to wider populations. In particular, raised Ig levels are probably not associated with freedom from CV events in patients with autoimmune conditions such rheumatoid arthritis and systemic lupus erythematosus in which there is a disease-related increase in risk of CV events and in which a polyclonal expansion of Ig levels signifies disease activity. Furthermore, our study has focused on the prediction of first adverse cardiovascular incidents in a high risk population, and does not address the relevance of immunoglobulins or specific antibodies during and after acute coronary events.

5. Conclusion {#s0070}
=============

In conclusion, our study suggests total serum IgG levels are strongly and independently associated with lower risk of CHD events in individuals with hypertension. Furthermore, IgG levels appear to significantly improve prediction beyond established risk predictors, even when including CRP and NtProBNP. As the measurement of total serum IgG is readily available to clinicians and relatively cheap, our findings have high potential for future clinical translation.
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![The number of subjects in different CV event risk categories with reclassification after inclusion of total serum IgG. The figure shows estimates of probabilities using the basic risk factor model without (vertical axis) and with (horizontal axis) inclusion of total serum IgG. Each cell includes the number of cases (clear background) and controls (shaded background). The basic risk factor model included age, sex, smoking status, diabetic status, baseline SBP, baseline TC, HDL, baseline creatinine values, BMI, family history of CHD, randomized BP and statin treatment.](gr2){#f0010}

![Percentage change in cardiovascular event cases and controls within the \< 10% risk and \> 10% CVD risk categories when total serum IgG added to the basic risk model.](gr3){#f0015}

###### 

Characteristics of the study population.

Table 1

  -------------------------------------------------------------------------------------------------------------------------------
                                        Controls\             Cases\                 p values
                                        (n = 1283)            (n = 470)              
  ------------------------------------- --------------------- ---------------------- --------------------------------------------
  Male                                  1089 (84.9%)          397 (84.5%)            0.83

  Age (years)                           65.30 (7.57)          65.34 (7.80)           0.93

  Current smokers                       272 (21.2%)           121 (25.7%)            0.043

  Alcohol: never                        279 (21.7%)           121 (25.7%)            0.21[⁎](#tf0010){ref-type="table-fn"}

  Alcohol: ≤ 14 (F)/21(M) units/week    753 (58.7%)           260 (55.3%)            

  Alcohol: \> 14 (F)/21(M) units/week   251 (19.5%)           89 (18.9%)             

  Completed education age (years):                                                   0.004[⁎](#tf0010){ref-type="table-fn"}

  ≤ 12                                  425 (33.2%)           176 (37.4%)            

  ≤ 15                                  590 (46.0%)           227 (48.3%)            

  ≤ 18                                  144 (11.2%)           45 (9.6%)              

  \> 18                                 123 (9.6%)            22 (4.7%)              

  SBP (mm Hg)                           161.82 (17.39)        164.63 (17.75)         0.003

  DBP (mm Hg)                           92.12 (9.72)          92.99 (10.41)          0.10

  Heart rate (bpm)                      70.27 (11.78)         69.74 (12.75)          0.42

  BMI (kg/m^2^)                         28.97 (4.51)          28.70 (4.03)           0.25

  Total cholesterol (mmol/L)            5.91 (1.07)           5.99 (1.07)            0.15

  LDL cholesterol (mmol/L)              3.79 (0.95)           3.92 (0.97)            0.012

  HDL cholesterol (mmol/L)              1.30 (0.35)           1.25 (0.32)            0.011

  Triglyceride (mmol/L)                 1.60 (1.20--2.30)     1.70 (1.20--2.20)      0.35[ǂ](#tf0005){ref-type="table-fn"}

  Glucose (mmol/L)                      5.60 (5.10--6.50)     5.60 (5.10--6.80)      0.17[ǂ](#tf0005){ref-type="table-fn"}

  Creatinine (μmol/L)                   99.20 (16.13)         102.63 (19.45)         0.0002

  CRP (mg/L)                            2.53 (1.27--4.97)     3.04 (1.55--5.53)      0.001[ǂ](#tf0005){ref-type="table-fn"}

  NtProBNP (pg/mL)                      84.50 (44.0--166.0)   111.00 (52.0--241.0)   \< 0.0001[ǂ](#tf0005){ref-type="table-fn"}

  Diabetes                              337 (26.3%)           145 (30.9%)            0.06

  Family history of coronary disease    218 (17.0%)           81 (17.2%)             0.90

  Amlodipine                            646 (50.4%)           220 (46.8%)            0.18

  BP treatment at baseline              1161 (90.5%)          429 (91.3%)            0.62
  -------------------------------------------------------------------------------------------------------------------------------

Values are mean (SD) or n (%). Missing: Triglyceride: 75, LDL-cholesterol, creatinine: 42, glucose: 79, CRP and NtProBNP: 4 each. Details of the 470 CV event cases: 343 CHD cases (108 non-fatal MI, 85 fatal CHD, 134 coronary revascularization and 16 had both revascularization and non-fatal MI); 127 stroke cases (100 ischemic strokes, 21 hemorrhagic strokes and 6 unspecified strokes).

Values are presented in median (interquartile range), p values by Wilcoxon--Mann--Whitney test.

p values for alcohol and education are χ^2^ statistics.

###### 

Median and interquartile range values of total serum IgM, total serum IgG and anti-MDA-LDL antibodies at baseline.

Table 2

  --------------------------------------------------------------------------------------------------
                                           Controls\              Cases\                 p value
                                           (n = 1283)             (n = 470)              
  ---------------------------------------- ---------------------- ---------------------- -----------
  Total serum IgG (U)\                     0.42 (0.37--0.47)\     0.40 (0.35--0.45)\     \< 0.0001
  (g/L)[⁎](#tf0015){ref-type="table-fn"}   15.88 (12.18--20.95)   14.35 (10.96--18.71)   

  Total serum IgM (U)\                     0.44 (0.31--0.60)\     0.40 (0.29--0.56)\     0.003
  (g/L)[⁎](#tf0015){ref-type="table-fn"}   1.31 (0.84--2.06)      1.16 (0.78--1.86)      

  IgG anti-MDA-LDL (U)                     0.44 (0.33--0.58)      0.42 (0.31--0.55)      0.02

  IgM anti-MDA-LDL (U)                     0.89 (0.59--1.20)      0.86 (0.56--1.13)      0.06
  --------------------------------------------------------------------------------------------------

Expressed as g/L as interpolated from standard curves. p values obtained by using Wilcoxon--Mann--Whitney test.

###### 

Spearman Partial Correlation (rho) between total serum IgM and IgG, IgM and IgG anti-MDA-LDL antibodies, CRP and NtProBNP.

Table 3

                     IgG anti-MDA-LDL                            IgM anti-MDA-LDL                           Total IgG                                  Total IgM                                  LDL-c                                     CRP     NtProBNP
  ------------------ ------------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------ ----------------------------------------- ------- ----------
  IgG anti-MDA-LDL   1.000                                                                                                                                                                                                                          
  IgM anti-MDA-LDL   0.233[⁎⁎⁎](#tf0030){ref-type="table-fn"}    1.000                                                                                                                                                                              
  Total serum IgG    0.363[⁎⁎⁎](#tf0030){ref-type="table-fn"}    0.151[⁎⁎⁎](#tf0030){ref-type="table-fn"}   1.000                                                                                                                                   
  Total serum IgM    0.149[⁎⁎⁎](#tf0030){ref-type="table-fn"}    0.779[⁎⁎⁎](#tf0030){ref-type="table-fn"}   0.185[⁎⁎⁎](#tf0030){ref-type="table-fn"}   1.000                                                                                        
  LDL-c              − 0.085[⁎⁎](#tf0025){ref-type="table-fn"}   0.002                                      − 0.033                                    0.010                                      1.000                                             
  CRP                0.129[⁎⁎⁎](#tf0030){ref-type="table-fn"}    0.031                                      0.089[⁎⁎](#tf0025){ref-type="table-fn"}    0.028                                      0.094[⁎⁎](#tf0025){ref-type="table-fn"}   1.000   
  NtProBNP           0.005                                       − 0.073[⁎](#tf0020){ref-type="table-fn"}   0.023                                      − 0.070[⁎](#tf0020){ref-type="table-fn"}   − 0.008                                   0.046   1.000

All data apart from LDL cholesterol (LDL-c) were log-transformed before correlation. Adjusted for age and sex.

p \< 0.05.

p \< 0.001.

p \< 0.0001.

###### 

Odds ratios of cardiovascular events (coronary heart disease or stroke) in relation to baseline total serum Igs and anti-MDA-LDL antibodies (per SD increase in log-transformed antibodies and in antibody tertiles).

Table 4

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                 Cases/\            Model 1            Model 2            Model 3            Model 4                                                                                  
                                                 controls                                                                                                                                                             
  ---------------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------ --
  Per 1 SD increase in log~e~ total IgG          0.80 (0.72,0.89)   \< 0.0001          0.81 (0.72,0.91)   0.0003                                                   0.81 (0.72,0.91)   0.0003                          

  Total serum IgG                                Low                180/406            1.00 (Ref)                            1.00 (Ref)                                                                  1.00 (Ref)   

  Mid                                            162/420            0.86 (0.67,1.11)   0.26               0.92 (0.70,1.20)   0.52                                                     0.97 (0.74,1.28)   0.83         

  High                                           128/458            0.62 (0.47,0.81)   0.0004             0.62 (0.46,0.82)   0.0007                                                   0.61 (0.46,0.82)   0.0008       

  Trend                                                             p = 0.0004                            p = 0.0008                                                                  p = 0.0009                      

  Per 1 SD increase in log~e~ total IgM          0.83 (0.75,0.93)   0.001              0.84 (0.75,0.94)   0.003                                                    0.85 (0.76,0.96)   0.006                           

  Total serum IgM                                Low                177/404            1.00 (Ref)                            1.00 (Ref)                                                                  1.00 (Ref)   

  Mid                                            160/429            0.82 (0.63,1.06)   0.13               0.82 (0.62,1.07)   0.15                                                     0.85 (0.65,1.13)   0.26         

  High                                           133/451            0.65 (0.49,0.85)   0.002              0.67 (0.51,0.89)   0.005                                                    0.70 (0.53,0.93)   0.014        

  Trend                                                             p = 0.0016                            p = 0.005                                                                   p = 0.014                       

  Per 1 SD increase in log~e~ IgG anti-MDA-LDL   0.88 (0.79,0.98)   0.016              0.89 (0.79,0.99)   0.040              0.96 (0.85,1.08)   0.46               0.87 (0.78,0.98)   0.021                           

  IgG anti-MDA-\                                 Low                179/405            1.00 (Ref)                            1.00 (Ref)                            1.00 (Ref)                            1.00 (Ref)   
  LDL                                                                                                                                                                                                                 

  Mid                                            147/438            0.75 (0.58,0.97)   0.030              0.74 (0.57,0.97)   0.030              0.81 (0.61,1.07)   0.13               0.74 (0.57,0.98)   0.034        

  High                                           144/441            0.74 (0.57,0.96)   0.022              0.76 (0.58,1.00)   0.048              0.90 (0.67,1.20)   0.46               0.74 (0.56,0.97)   0.030        

  Trend                                                             p = 0.02                              p = 0.044                             p = 0.43                              p = 0.027                       

  Per 1 SD increase in log~e~ IgM anti-MDA-LDL   0.88 (0.79,0.98)   0.023              0.90 (0.80,1.00)   0.059              1.09 (0.90,1.32)   0.38               0.91 (0.81,1.02)   0.10                            

  IgM anti-MDA-LDL                               Low                166/418            1.00 (Ref)                            1.00 (Ref)                            1.00 (Ref)                            1.00 (Ref)   

  Mid                                            163/422            0.95 (0.73,1.23)   0.69               0.93 (0.71,1.21)   0.58               1.16 (0.84,1.59)   0.37               0.94 (0.71,1.24)   0.66         

  High                                           141/444            0.76 (0.58,0.98)   0.037              0.81 (0.61,1.06)   0.13               1.18 (0.80,1.75)   0.40               0.84 (0.64,1.11)   0.22         

  Trend                                                             p = 0.038                             p = 0.10                              p = 0.41                              p = 0.22                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Model 1: unadjusted but matched for age and sex; model 2: adjusted for smoking status, diabetic status, baseline SBP, baseline total cholesterol, HDL, baseline creatinine, BMI, family history of coronary disease, randomized BP and statin treatments; model 3: adjusted as in model 2 plus either total IgG or IgM; model 4: adjusted in model 2 plus log~e~ CRP and NtProBNP. Immunoglobulin and specific antibody tertile levels in Units (U) as measured by ELISA and (in g/L as interpolated per standard curves for total Ig levels) were: total IgG: Low \< 0.384 (\< 13.11 g/L), Mid 0.3845--0.4465 (13.12--18.40 g/L), High \> 0.4465 (18.4 g/L); total IgM Low \< 0.3440 (\< 0.95 g/L), Mid 0.3445--0.5305 (0.96--1.71 g/L), High \> 0.5305 (\> 1.71 g/L); IgG anti-MDA-LDL Low \< 0.3626, Mid 0.3637--0.5205, High \> 0.05205; IgM anti-MDA-LDL: Low \< 0.6825, Mid 0.6835--1.0628, High \> 1.0628.

###### 

Odds ratios of events due to coronary heart disease in relation to baseline total serum Igs and anti-MDA-LDL antibodies (per SD increase in log-transformed antibodies and in antibody tertiles).

Table 5

                                                 Cases/controls   Model 1            Model 2      Model 3            Model 4                                                                      
  ---------------------------------------------- ---------------- ------------------ ------------ ------------------ ------------ ------------------ ------------ ------------------ ------------ --
  Per 1 SD increase in log~e~ total IgG          343/939          0.66 (0.57,0.76)   \< 0.0001    0.68 (0.58,0.79)   \< 0.0001                                    0.68 (0.58,0.79)   \< 0.0001    
  Total serum IgG                                Low              153/309            1.00 (Ref)                      1.00 (Ref)                                                      1.00 (Ref)   
  Mid                                            120/301          0.79 (0.59,1.06)   0.12         0.83 (0.61,1.13)   0.23                                         0.89 (0.64,1.22)   0.45         
  High                                           70/329           0.42 (0.30,0.59)   \< 0.0001    0.43 (0.30,0.61)   \< 0.0001                                    0.43 (0.30,0.62)   \< 0.0001    
  Trend                                                           p \< 0.0001                     p \< 0.0001                                                     p \< 0.0001                     
                                                                                                                                                                                                  
  Per 1 SD increase in log~e~ total IgM          343/939          0.81 (0.71,0.93)   0.002        0.82 (0.71,0.94)   0.005                                        0.83 (0.72,0.95)   0.008        
  Total serum IgM                                Low              134/296            1.00 (Ref)                      1.00 (Ref)                                                      1.00 (Ref)   
  Mid                                            124/326          0.82 (0.61,1.11)   0.19         0.84 (0.61,1.15)   0.28                                         0.88 (0.64,1.22)   0.44         
  High                                           85/317           0.57 (0.41,0.80)   0.001        0.59 (0.42,0.83)   0.003                                        0.62 (0.43,0.87)   0.007        
  Trend                                                           p = 0.001                       p = 0.003                                                       p = 0.007                       
                                                                                                                                                                                                  
  Per 1 SD increase in log~e~ IgG anti-MDA-LDL   343/939          0.83 (0.73,0.94)   0.003        0.85 (0.74,0.98)   0.020        0.98 (0.84,1.13)   0.77         0.83 (0.72,0.95)   0.008        
  IgG anti-MDA-LDL                               Low              142/302            1.00 (Ref)                      1.00 (Ref)                      1.00 (Ref)                      1.00 (Ref)   
  Mid                                            106/320          0.70 (0.52,0.94)   0.018        0.67 (0.49,0.91)   0.012        0.81 (0.59,1.13)   0.22         0.67 (0.49,0.92)   0.015        
  High                                           95/317           0.64 (0.47,0.87)   0.005        0.70 (0.50,0.97)   0.031        0.95 (0.66,1.35)   0.76         0.66 (0.47,0.93)   0.016        
  Trend                                                           p = 0.004                       p = 0.023                       p = 0.71                        p = 0.012                       
                                                                                                                                                                                                  
  Per 1 SD increase in log~e~ IgM anti-MDA-LDL   343/939          0.88 (0.77,0.99)   0.038        0.89 (0.78,1.02)   0.09         1.12 (0.89,1.40)   0.33         0.90 (0.78,1.03)   0.12         
  IgM anti-MDA-LDL                               Low              123/308            1.00 (Ref)                      1.00 (Ref)                      1.00 (Ref)                      1.00 (Ref)   
  Mid                                            123/310          0.97 (0.72,1.31)   0.86         0.96 (0.70,1.32)   0.80         1.20 (0.83,1.73)   0.33         0.96 (0.69,1.33)   0.80         
  High                                           97/321           0.72 (0.53,0.99)   0.043        0.78 (0.56,1.09)   0.14         1.18 (0.74,1.86)   0.49         0.81 (0.58,1.13)   0.22         
  Trend                                                           p = 0.046                       p = 0.15                        p = 0.49                        p = 0.22                        

Model 1: unadjusted but matched for age and sex; model 2: adjusted for smoking status, diabetic status, baseline SBP, baseline total cholesterol, HDL, baseline creatinine, BMI, family history of coronary disease, randomized BP and statin treatments; model 3: adjusted as in model 2 plus either total IgG or IgM; model 4: adjusted in model 2 plus log~e~ CRP and NtProBNP. Immunoglobulin and specific antibody tertile levels in Units (U) as measured by ELISA and (in g/L as interpolated per standard curves for total Ig levels) were: total IgG: Low \< 0.384 (\< 13.11 g/L), Mid 0.3845--0.4465 (13.12--18.40 g/L), High \> 0.4465 (18.4 g/L); total IgM Low \< 0.3440 (\< 0.95 g/L), Mid 0.3445--0.5305 (0.96--1.71 g/L), High \> 0.5305 (\> 1.71 g/L); IgG anti-MDA-LDL Low \< 0.3626, Mid 0.3637--0.5205, High \> 0.05205; IgM anti-MDA-LDL: Low \< 0.6825, Mid 0.6835--1.0628, High \> 1.0628.

###### 

Measures of model fit and reclassification by adding each variable in turn to the basic CV events model using unconditional logistic regression model.

Table 6

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            Basic[ǂ](#tf0035){ref-type="table-fn"}   Total serum IgG     Total serum IgM    IgG anti-MDA-LDL    IgM anti-MDA-LDL   All 4[§](#tf0040){ref-type="table-fn"}
  ------------------------- ---------------------------------------- ------------------- ------------------ ------------------- ------------------ ----------------------------------------
  Goodness of fit                                                                                                                                  

  LR χ^2^ (df)              65.77 (13)                               79.57 (14)          75.17 (14)         70.12 (14)          68.97 (14)         87.78 (17)

  p value                   Ref                                      0.0002              0.002              0.04                0.07               0.0002

                                                                                                                                                   

  Calibration                                                                                                                                      

  Hosmer-Lemeshow           8.17                                     7.07                3.98               7.7                 8.74               3.96

  χ^2^, deciles             p = 0.42                                 0.53                0.86               0.46                0.36               0.86

                                                                                                                                                   

  Discrimination                                                                                                                                   

  AUROC                     0.6213\                                  0.6391\             0.6293\            0.6270\             0.6241\            0.6421\
                            (0.5921,0.6505)                          (0.6096,0.6686)     (0.6000,0.6586)    (0.5978,0.6563)     (0.5948,0.6533)    (0.6127,0.6715)

  p (difference)            Ref                                      0.009               0.18               0.16                0.45               0.011

  p (total IgG vs. all 4)                                            Ref                                                                           0.54

                                                                                                                                                   

  Reclassification                                                                                                                                 

  IDI                       Ref                                      0.90% p \< 0.0001   0.59% p = 0.003    0.27% p = 0.03      0.20% p = 0.066    1.38% p \< 0.0001

  Continuous NRI            Ref                                      17.59% p = 0.001    16.67% p = 0.002   8.65% p = 0.11      6.05% p = 0.26     17.40% p = 0.001

  Categorical NRI           Ref                                      7.54% p \< 0.0001   1.18% p = 0.47     4.52% p \< 0.0001   1.14% p = 0.32     8.27% p \< 0.0001
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Adjusted for age, sex, smoking status, diabetic status, baseline SBP, baseline total cholesterol, HDL, baseline creatinine values, BMI, family history of CHD, randomized BP and statin treatments.

Basic model plus IgG anti-MDA-LDL, IgM anti-MDA-LDL, total serum IgG and total serum IgM.

[^1]: Joint senior author.
